Literature DB >> 12040458

CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice.

H Mizuguchi1, N Koizumi, T Hosono, A Ishii-Watabe, E Uchida, N Utoguchi, Y Watanabe, T Hayakawa.   

Abstract

Targeted gene delivery to the tissue of interest by recombinant adenovirus (Ad) vectors is limited by the relatively broad expression of the primary receptor, the coxsackievirus and adenovirus receptor (CAR), and the secondary receptor, alphav integrin. This problem could be overcome by mutating the fiber and penton base, which bind with CAR and alphav integrin, respectively. In this study, we constructed CAR-binding ablated Ad vectors and alphav integrin-binding ablated Ad vectors by mutation in the FG loop of fiber knob and in the RGD motif of penton base, respectively, and compared the gene transfer properties of their vectors into various types of cultured cells and mice with conventional Ad vectors. We also generated Ad vectors containing RGD peptide in the HI loop of the fiber knob. CAR-binding ablated Ad vectors mediated about 1% of gene transfer activity into CAR-positive cultured cells, compared with conventional Ad vectors, while alphav integrin-binding ablated Ad vectors maintained at least 76% of gene transfer activity into cultured CAR-positive cells. Inclusion of the RGD peptide into the HI loop of the fiber knob of CAR-binding ablated Ad vectors restored gene transfer activity in vitro. On the other hand, systemically administered CAR-binding ablated Ad vectors, as well as alphav integrin-binding ablated Ad vectors mediated similar levels of gene transfer into mouse liver with the conventional Ad vectors. These results suggest that continued interaction of either the fiber with CAR or the penton base with alphav integrin offers an effective route of virus entry into mouse liver in vivo. Inhibition of the interaction of both the fiber with CAR and the penton base with alphav integrin is likely to be crucial to the development of targeted Ad vectors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040458     DOI: 10.1038/sj.gt.3301701

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  30 in total

Review 1.  Targeting gene therapy vectors to the vascular endothelium.

Authors:  Lorraine M Work; Stuart A Nicklin; Andrew H Baker
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

2.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 4.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 5.  Adenovirus receptors.

Authors:  Yuanming Zhang; Jeffrey M Bergelson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 6.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

7.  Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.

Authors:  Zhen Wang; Baoming Wang; Junfang Lou; Jingyi Yan; Lei Gao; Ranshen Geng; Bin Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 8.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

9.  Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.

Authors:  Quinn K T Ng; Marie K Sutton; Pan Soonsawad; Li Xing; Holland Cheng; Tatiana Segura
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

10.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.